Cepheid's Q1 Revenues Increase 19 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Cepheid reported after the close of the market Thursday that its first-quarter revenues rose 19 percent year over year as reagent and disposable sales increased 22 percent.

The Sunnyvale, Calif.-based firm said that total revenues came in at $91.9 million, up from $77.3 million a year ago, and topping the average analyst estimate of $89.1 million.

Reagent and disposable sales shot up to $75.9 million from $62.1 million a year ago, while system and other sales increased 5 percent to $16.0 million from $15.2 million a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.